• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Genomically Targeted Therapy Delays Advanced Breast Cancer Progression

  • — 31 Oct, 2018
Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
Genomic Targeting Brings Benefit in Advanced Pre-Treated Breast Cancer
Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
00:00 / 6 m ins
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed

Subscribe: Apple Podcasts | Spotify | Stitcher

 

 

MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestrant in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer in the randomized phase three SOLAR-1 trial reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO.

“This study opens the door for precision medicine in metastatic breast cancer,” said lead investigator Fabrice André MD PhD, Associate Professor in the Department of Medical Oncology at Institut Gustave Roussy in Villejuif, France. This had been the first study to show statistically significant clinically meaningful PFS improvement with an alpha isoform-specific PI3K inhibitor in patients with HR+ HER2- advanced breast cancer and mutated oncogene PIK3CA, he said, and the drug had a “manageable toxicity profile”.

“[This] alpha selective PI3 kinas inhibitor improves progression free survival in a clinically meaningful way in patients who present [with] mutational PI3 kinase,” André tells the Audio Journal of Oncology. He noted that SOLAR-1 had been the first study to show a benefit from a targeted therapy driven by genomics.

You may also like...

  • Niraparib Quadruples Progression Free Survival in Platinum-Sensitive Ovarian Cancer Niraparib Quadruples Progression Free Survival in Platinum-Sensitive Ovarian Cancer 21 Oct, 2016
  • ASCO Audio Journal of Oncology – September 1st, 2006 ASCO Audio Journal of Oncology – September 1st, 2006 30 Aug, 2006
  • Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers 19 Nov, 2013
  • Andrew Loblaw Low risk localized prostate cancer: no harm from waiting! 24 Mar, 2013
  • Previous story Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy
  • Next story PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • New Front Line Standard for Older Patients with Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
  • Home
  • Oncology
  • AJO
  • Genomically Targeted Therapy Delays Advanced Breast Cancer Progression

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.